While LTβR-deficient patients generally fare well with IVIG replacement therapy, NIK-deficient patients exhibit severe, life-threatening combined immunodeficiency with increased susceptibility to bacterial, viral, and protozoan infections, often necessitating HSCT as a life-saving intervention (17, 18). The gene discussed is MAP3K14; the disease is immune system disorder.